Browse the corpus

Acid phosphatase is an enzyme that catalyzes the hydrolysis of phosphate esters in an acidic environment. This chemical reaction is crucial for various metabolic processes. Therefore, acid phosphatase exists in several biological kingdoms, including plants, animals, fungi, and bacteria. Research has shown that acid phosphatase plays a crucial role in various physiological processes in humans, including bone resorption, immune defense, pathogen clearance, epithelial growth regulation, and iron transport.[1]

The acid phosphatase family is generally divided into 2 major groups based on the presence or absence of a binuclear metal center. The first group, known as metallohydrolases, exhibits a characteristic purple color due to a charge transfer between a tyrosine residue and Fe(III) at the active site. These enzymes are known as purple acid phosphatases. These enzymes are also referred to as tartrate-resistant acid phosphatases because they are not inhibited by tartrate. This resistance is utilized in biochemical assays to distinguish it from other types of acid phosphatase.[2][3][4][5]

Treatment with sipuleucel-T requires coordination from a multidisciplinary team, including an oncologist, a pharmacist, infusion room nurses, and clinic nurses. The process begins with leukapheresis, where the patient's blood is collected. The blood sample is then sent to the manufacturing facility, where the harvested antigen-presenting cells are incubated with recombinant prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor, thereby activating the antigen-presenting cells. The activated antigen-presenting cells are then packed and returned to the infusion center, where they are infused into the patient. The approved treatment regimen involves biweekly infusions. The cost of sipuleucel-T is approximately $100,000 per month, making it one of the most expensive cancer treatments on the market. Although sipuleucel-T has shown superior efficacy to docetaxel, the cost difference may barely compensate for the added median life; therefore, funding becomes an obstacle. Fortunately, the Centers for Medicare and Medicaid cover sipuleucel-T treatments. Nonetheless, involving financial personnel and social workers in the treatment process may facilitate funding. In addition, exploring equally effective yet less expensive options is certainly warranted to decrease the economic burden on society.[41][42]